Search results for "myocardial ischemia"

showing 10 items of 106 documents

Guanxin Danshen Formulation Protects against Myocardial Ischemia Reperfusion Injury-Induced Left Ventricular Remodeling by Upregulating Estrogen Rece…

2017

Background: Guanxin Danshen formulation (GXDSF) is a traditional Chinese herbal recipe recorded in the Chinese Pharmacopoeia since 1995 edition, which consists of Salviae miltiorrhizae Radix et Rhizoma, Notoginseng Radix et Rhizoma and Dalbergiae odoriferae Lignum. Our previous research suggested GXDSF had positive effect on cardiovascular disease. Therefore, the aim of this study was to elucidate the effects of GXDSF on myocardial ischemia reperfusion injury-induced left ventricular remodelling (MIRI-LVR). Methods: The effects of GXDSF on cardiac function were detected by haemodynamics and echocardiograms. The effects of GXDSF on biochemical parameters (AST, LDH and CK-MB) were analysed. H…

0301 basic medicineCardiac function curvemedicine.medical_specialtyGuanxin Danshen formulaEstrogen receptor030204 cardiovascular system & hematologyPharmacologyventricular remodeling03 medical and health sciences0302 clinical medicineFibrosisInternal medicinemedicinenetwork pharmacologyPharmacology (medical)Ventricular remodelingOriginal ResearchPharmacologyPI3K/AktEjection fractionbusiness.industryestrogen receptor βlcsh:RM1-950PHTPPmedicine.diseasemyocardial ischemia reperfusion injury030104 developmental biologylcsh:Therapeutics. PharmacologyCardiologyMyocardial fibrosisbusinessReperfusion injuryFrontiers in Pharmacology
researchProduct

Cardioprotection and natural polyphenols: An update of clinical and experimental studies

2018

Myocardial ischemia is the leading cause of death worldwide. Despite better outcomes with early coronary artery reperfusion strategies, morbidity and mortality remain significant. The principal myocardial hallmark of myocardial ischemia is cell death and the associated impairment of cardiac contractility. In this way, the use of extracts from medicinal plants versus synthetic drugs to mitigate post-ischemic damage constitutes an alternative. Despite their proven beneficial effects in cardiovascular disorders, the use of many plants is questioned. Our aim is to update the clinical and experimental studies about the actions of medicinal plants and polyphenol-enriched extracts against ischemia…

0301 basic medicineCardiotonic AgentsMyocardial ischemiaCIENCIAS MÉDICAS Y DE LA SALUDMyocardial IschemiaMEDLINE030204 cardiovascular system & hematologyFisiologíaNATURAL PRODUCTS03 medical and health sciencesISCHEMIA-REPERFUSIONCARDIOPROTECTION0302 clinical medicineWeb of knowledgeMITOCHONDRIAAnimalsHumansMedicineCardioprotective AgentMedicinal plantsBeneficial effectsCause of deathCardioprotectionClinical Trials as TopicTraditional medicinePlant Extractsbusiness.industryPolyphenolsfood and beveragesGeneral MedicineMedicina Básica030104 developmental biologybusinessFood Science
researchProduct

Bi-layered polyurethane – Extracellular matrix cardiac patch improves ischemic ventricular wall remodeling in a rat model

2016

As an intervention to abrogate ischemic cardiomyopathy, the concept of applying a temporary, local patch to the surface of the recently infarcted ventricle has been explored from a number of design perspectives. Two important features considered for such a cardiac patch include the provision of appropriate mechanical support and the capacity to influence the remodeling pathway by providing cellular or biomolecule delivery. The objective of this report was to focus on these two features by first evaluating the incorporation of a cardiac extracellular matrix (ECM) component, and second by evaluating the impact of patch anisotropy on the pathological remodeling process initiated by myocardial …

0301 basic medicineMaterials scienceAngiogenesisPolyurethanesBiophysicsMyocardial IschemiaInfarctionBiocompatible MaterialsBioengineeringCeramics and Composite02 engineering and technologyCardiac ECMBiomaterialsExtracellular matrixRats Sprague-Dawley03 medical and health sciencesVentricular Dysfunction LeftAbsorbable ImplantsMaterials TestingmedicineAnimalsMyocardial infarctionCardiac patchIschemic cardiomyopathyTissue ScaffoldsVentricular RemodelingVentricular wallHydrogelsRecovery of Function021001 nanoscience & nanotechnologymedicine.diseaseBiomaterialExtracellular MatrixRatsCompliance (physiology)Electrospun scaffold030104 developmental biologymedicine.anatomical_structureTreatment OutcomeBiophysicVentricleRats Inbred LewMechanics of MaterialsCeramics and CompositesFemale0210 nano-technologyStructure - functionBiomedical engineering
researchProduct

The TRPA1 Channel in the Cardiovascular System: Promising Features and Challenges.

2019

The transient receptor potential ankyrin 1 (TRPA1) channel is a calcium-permeable nonselective cation channel in the plasma membrane that belongs to the transient receptor potential (TRP) channel superfamily. Recent studies have suggested that the TRPA1 channel plays an essential role in the development and progression of several cardiovascular conditions, such as atherosclerosis, heart failure, myocardial ischemia–reperfusion injury, myocardial fibrosis, arrhythmia, vasodilation, and hypertension. Activation of the TRPA1 channel has a protective effect against the development of atherosclerosis. Furthermore, TRPA1 channel activation elicits peripheral vasodilation and induces a biphasic bl…

0301 basic medicinemedicine.medical_specialtyhypertensionheart failureVasodilationReviewTRPA1 Channelarrhythmia03 medical and health sciencesTransient receptor potential channel0302 clinical medicineInternal medicinemedicineTRPA1 channelAnkyrinPharmacology (medical)vasodilationchemistry.chemical_classificationPharmacologybusiness.industrylcsh:RM1-950food and beveragesmedicine.diseaseBlockademyocardial ischemia–reperfusion injurylcsh:Therapeutics. Pharmacology030104 developmental biologyBlood pressurechemistry030220 oncology & carcinogenesisHeart failureCardiologyMyocardial fibrosismyocardial fibrosisatherosclerosisbusinesspsychological phenomena and processesFrontiers in pharmacology
researchProduct

Corrigendum: Seabuckthorn Pulp Oil Protects against Myocardial Ischemia–Reperfusion Injury in Rats through Activation of Akt/eNOS

2016

Seabuckthorn (SBT) pulp oil obtained from the fruits of seabuckthorn [Hippophae rhamnoides L. (Elaeagnaceae)] has been used traditionally for its medicinal and nutritional properties. However, its role in ischemia–reperfusion (IR) injury of myocardium in rats has not been elucidated so far. The present study reports the cardioprotective effect of SBT pulp oil in IR-induced model of myocardial infarction in rats and underlying mechanism mediating activation of Akt/eNOS signaling pathway. Male albino Wistar rats were orally administered SBT pulp oil (5, 10, and 20 ml/kg/day) or saline for 30 days. On the day 31, ischemia was induced by one-stage ligation of left anterior descending coronary a…

0301 basic medicinenatural productsIschemia030204 cardiovascular system & hematologyPharmacologyseabuckthornmedicine.disease_causeLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnosLactate dehydrogenaseMedicineoxidative stressPharmacology (medical)Original ResearchPharmacologylehberrybiologybusiness.industrylcsh:RM1-950apoptosisCorrectionbiology.organism_classificationmedicine.diseaseMalondialdehydemyocardial ischemia–reperfusion injury030104 developmental biologylcsh:Therapeutics. PharmacologyBiochemistrychemistryinflammationedible oilPulp (tooth)businessReperfusion injuryOxidative stressFrontiers in Pharmacology
researchProduct

Physiological and metabolic actions of mycophenolate mofetil on cultured newborn rat cardiomyocytes in normoxia and in simulated ischemia

2004

Mycophenolate mofetil (MMF) is a new immunosuppressive drug used to reduce acute rejection after heart transplantation. As with other immunosuppressive drugs, MMF therapy is associated with several adverse effects. However, the direct effects of MMF on myocardial tissue has not been yet evaluated. The aim of the work was thus to evaluate the effects of MMF on isolated cardiomyocytes (CM) in normal conditions and in an in vitro model of simulated ischemia (SI; substrate-free hypoxia) and reperfusion (R; reoxygenation). Myocyte-enriched cultures were prepared from newborn rat heart ventricles. The transmembrane potentials were recorded using conventional microelectrodes and the cell contracti…

Adenosinemedicine.medical_treatmentMyocardial IschemiaIschemiaMyocardial ReperfusionPharmacologyMycophenolateXanthineMembrane Potentialschemistry.chemical_compoundmedicineAnimalsMyocytes CardiacPharmacology (medical)Rats WistarCells CulturedHypoxanthinePharmacologyHeart transplantationHypoxanthineMycophenolic AcidHypoxia (medical)medicine.diseaseXanthineCell HypoxiaRatsElectrophysiologyImmunosuppressive drugAnimals NewbornchemistryAnesthesiamedicine.symptomImmunosuppressive AgentsFundamental and Clinical Pharmacology
researchProduct

Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocard…

2007

N-terminal pro-b-type natriuretic peptide (NT pro-BNP) is a neurohormone synthesized predominantly in ventricular myocardium. In patients with symptoms of heart failure, elevation in NT pro-BNP accurately identifies ventricular dysfunction. However, NT pro-BNP levels are not specific for ventricular dysfunction in patients who do not have overt symptoms of heart failure, suggesting that other cardiac processes such as myocardial ischemia may also cause elevation in NT pro-BNP. The study was aimed to determine whether NT pro-BNP elevations are associated with myocardial ischemia.One hundred and thirty patients (104 males, 26 females, mean age 61+12 years), with ST elevation acute myocardial …

AdultAged 80 and overMaleTomography Emission-Computed Single-PhotonMyocardial InfarctionMyocardial IschemiaOrganotechnetium CompoundsMiddle AgedSensitivity and SpecificityPeptide FragmentsElectrocardiographyLogistic ModelsOrganophosphorus CompoundsROC CurvePredictive Value of TestsNatriuretic Peptide BrainExercise TestOdds RatioHumansFemaleRadiopharmaceuticalsBiomarkersAgedEchocardiography StressRetrospective Studies
researchProduct

MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing

2000

Beta-blocker therapy results in a functional benefit in patients with heart failure (CHF) due to idiopathic dilated cardiomyopathy (DCM). This study assessed if similar effects were observed in patients with ischemic heart disease (CAD), NYHA II–III after 6 months of therapy with metoprolol. Methods and results: Fifty-two patients with CHF secondary to DCM (26 patients) and CAD (26 patients) and a left ventricular ejection fraction (EF) < 40% were enrolled in the placebo-controlled study. The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day. Three patients died due to cardiogenic shock, two received placebo and one metoprolol. Eight patients did not complete …

AdultCardiomyopathy DilatedMaleCardiac function curvemedicine.medical_specialtyCardiac VolumeAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyVentricular Function LeftDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathyHeart ratemedicineHumansProspective Studiescardiovascular diseasesAgedMetoprololHeart FailureEjection fractionbusiness.industryCardiogenic shockMiddle Agedmedicine.diseaseHeart failureExercise Testcardiovascular systemCardiologyFemaleCardiology and Cardiovascular Medicinebusinesshuman activitiesMetoprololcirculatory and respiratory physiologymedicine.drugEuropean Journal of Heart Failure
researchProduct

Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure etiology and correlates to clinical variables.

2012

Downregulation of β1- adrenergic receptors (β1-ARs) and increased expression/function of G-protein-coupled receptor kinase 2 (GRK2) have been observed in human heart failure, but changes in expression of other ARs and GRKs have not been established. Another unresolved question is the incidence of these compensatory mechanisms depending on heart failure etiology and treatment. To analyze these questions, we quantified the mRNA/protein expressions of six ARs (α1A, α1B, α1D, β1, β2, and β3) and three GRKs (GRK2, GRK3, and GRK5) in left (LV) and right ventricle (RV) from four donors, 10 patients with ischemic cardiomyopathy (IC), 14 patients with dilated cardiomyopathy (DC), and 10 patients wit…

AdultCardiomyopathy DilatedMalemedicine.medical_specialtyGenotypePhysiologyCardiomyopathyMyocardial IschemiaVentricular Function LeftPhysiology (medical)Internal medicinemedicineHumansRNA MessengerHeart FailureAnalysis of VarianceEjection fractionIschemic cardiomyopathybiologybusiness.industryBeta adrenergic receptor kinaseMyocardiumDilated cardiomyopathyStroke VolumeStroke volumeMiddle Agedmedicine.diseaseG-Protein-Coupled Receptor KinasesReceptors AdrenergicEndocrinologymedicine.anatomical_structurePhenotypeVentricleSpainHeart failurebiology.proteinCardiologyLinear ModelsFemaleCardiology and Cardiovascular MedicinebusinessCardiomyopathiesAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Prevalence of obesity and ischaemic heart disease in hypertensive subjects

1997

In the present study the prevalence of obesity and its association with ischemic heart disease, recognized according to clinical criteria (chest pain or previous infarction) and/or instrumental data, were described in 8,847 normotensive subjects and in 867 hypertensive subjects, hospitalized during a ten years period (1983-1992), through a cross-sectional study. In view of this all the subjects were considered as lean or obese according to their body mass index (BMI) and to sex specific cut-off values reported in the Italian Consensus Conference on Obesity. In particular, according to BMI values, the subjects were grouped as lean, overweight, moderate and severe obese subjects. Our results …

AdultMaleSettore MED/09 - Medicina InternaMyocardial IschemiaObesity Hypertension Cardiovascular diseaseMiddle AgedSettore MED/11 - Malattie Dell'Apparato CardiovascolareItalyHypertensionHumansFemaleObesityAged
researchProduct